Bydureon Bcise (Exenatide Microspheres) Patent Expiration, LOE Window & CMS Spending

Bydureon Bcise (Exenatide Microspheres) by AstraZeneca: FDA Orange Book core substance LOE 2026-04-04 (last listed 2031-04-04), 0 AB generics, $267.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN209210 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2026-04-04
Last Listed Patent or Exclusivity Date2031-04-04
Orange Book Patents (*PED Extensions)14 patents (7 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$267.7M
2024 Medicare Part D Spend$215.4M
2024 Medicaid Spend$52.3M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.